BB&T Corp Buys 4,627 Shares of Amgen Inc. (AMGN)
BB&T Corp increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.6% during the second quarter, Holdings Channel reports. The firm owned 87,248 shares of the medical research company’s stock after buying an additional 4,627 shares during the period. BB&T Corp’s holdings in Amgen were worth $15,027,000 as of its most recent filing with the SEC.
A number of other large investors also recently modified their holdings of AMGN. Bank of New York Mellon Corp increased its stake in shares of Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock worth $1,403,676,000 after buying an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of Amgen by 1.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock worth $474,947,000 after buying an additional 45,403 shares during the period. Bank of Montreal Can increased its stake in shares of Amgen by 10.5% in the first quarter. Bank of Montreal Can now owns 2,837,456 shares of the medical research company’s stock worth $465,543,000 after buying an additional 269,586 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of Amgen by 3.1% in the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock worth $446,250,000 after buying an additional 81,362 shares during the period. Finally, Swiss National Bank increased its stake in shares of Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares during the period. Institutional investors and hedge funds own 79.53% of the company’s stock.
Shares of Amgen Inc. (NASDAQ AMGN) traded down 1.94% during mid-day trading on Thursday, hitting $170.19. The stock had a trading volume of 951,359 shares. The stock’s 50-day moving average is $174.67 and its 200 day moving average is $167.36. The firm has a market cap of $124.18 billion, a PE ratio of 15.50 and a beta of 1.35. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $184.21.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.84 earnings per share. Equities research analysts predict that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a dividend of $1.15 per share. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.65%. Amgen’s payout ratio is currently 41.93%.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/bbt-corp-buys-4627-shares-of-amgen-inc-amgn/1471351.html.
AMGN has been the topic of a number of recent research reports. ValuEngine downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Finally, Argus upped their price objective on Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.